APA (7th ed.) Citation

Kitson, G., Byford, M., Cass, L., Howat, D., Köhn, B., Bisquera, A., . . . Thomson, D. (2025). A Phase II, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of HEX17, a Novel Broad-Spectrum Antiviral Drug, in a Controlled Human Infection Model of Influenza Challenge. Infectious Diseases & Therapy, 14(8), 1697. https://doi.org/10.1007/s40121-025-01179-2

Chicago Style (17th ed.) Citation

Kitson, Geoff, Marion Byford, Lindsey Cass, David Howat, Brigitte Köhn, Alessandra Bisquera, Andrew Catchpole, Nicolas Noulin, and Douglas Thomson. "A Phase II, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of HEX17, a Novel Broad-Spectrum Antiviral Drug, in a Controlled Human Infection Model of Influenza Challenge." Infectious Diseases & Therapy 14, no. 8 (2025): 1697. https://doi.org/10.1007/s40121-025-01179-2.

MLA (9th ed.) Citation

Kitson, Geoff, et al. "A Phase II, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of HEX17, a Novel Broad-Spectrum Antiviral Drug, in a Controlled Human Infection Model of Influenza Challenge." Infectious Diseases & Therapy, vol. 14, no. 8, 2025, p. 1697, https://doi.org/10.1007/s40121-025-01179-2.